Proportions of patients with WT1 and PRAME transcript levels, according to blast percentage, WHO classification, cytogenetics, and IPSS-R. Data are shown for the percentage of blasts in bone marrow aspirate (A), WHO classification (B), cytogenetics (C), and IPSS-R (D) at the time of MDS diagnosis. Overexpression of WT1 and PRAME were associated with elevated blast percentage (defined as ≥5%; P = .000 and P = .000 for WT1 and PRAME, respectively) (A), worse cytogenetics (P = .000 and P = .000 for WT1 and PRAME, respectively) (C), and IPSS-R higher risk (P = .000 and P = .000 for WT1 and PRAME, respectively) (D).